Morgan Stanley slashed its price target on Moderna Inc (BMV:MRNA) (NASDAQ:MRNA) to $38 from $70 given the lowered revenue guidance and ongoing competitive pressures in the vaccine market.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback